Cross-Resistance: One Cancer Therapy Can Undermine the Next
Cross-Resistance: One Cancer Therapy Can Undermine the Next
Targeted cancer therapy may jeopardize the effectiveness of subsequent immunotherapy by reducing dendritic cell numbers and activation, according to study of mice and patient samples.
Cross-Resistance: One Cancer Therapy Can Undermine the Next
Cross-Resistance: One Cancer Therapy Can Undermine the Next

Targeted cancer therapy may jeopardize the effectiveness of subsequent immunotherapy by reducing dendritic cell numbers and activation, according to study of mice and patient samples.

Targeted cancer therapy may jeopardize the effectiveness of subsequent immunotherapy by reducing dendritic cell numbers and activation, according to study of mice and patient samples.

immunotherapy
Homing Technology Delivers Therapy to Cancerous Bone
Homing Technology Delivers Therapy to Cancerous Bone
Roni Dengler, PhD | Jul 19, 2021
A clever approach to modifying already existing cancer therapies may be a game changer for treating metastatic breast cancer.
Updated
Biogen’s Alzheimer’s Drug Gets FDA Approval, Mixed Reviews
Biogen’s Alzheimer’s Drug Gets FDA Approval, Mixed Reviews
Kerry Grens | Jun 7, 2021
A lackluster performance in clinical trials of the monoclonal antibody aducanumab has left some experts unconvinced of its benefit.
Manipulating the Microbiome to Manage Disease
Manipulating the Microbiome to Manage Disease
The Scientist Creative Services Team in collaboration with Tecan | May 28, 2021
Cammie Lesser will discuss how she turns a probiotic into a drug-delivering machine, while Andrew Y. Koh will describe the connection between the gut microbiota and cancer immunotherapy efficacy.
Brain’s Lymphatic System Tied to Alzheimer’s Symptoms in Mice
Brain’s Lymphatic System Tied to Alzheimer’s Symptoms in Mice
Amanda Heidt | May 4, 2021
A dysfunctional lymphatic system, described as a clogging of the brain’s sink, may explain why immunotherapies fail in some Alzheimer’s patients.
LabTalk Podcast - A Modern Trojan Horse: Delivering Combination Immunotherapies to Solid Tumors 
LabTalk Podcast - A Modern Trojan Horse: Delivering Combination Immunotherapies to Solid Tumors 
The Scientist Creative Services Team in Collaboration with IsoPlexis | Apr 26, 2021
Katie McKenna discusses a combination CAR T and viral therapy that kills solid tumors.
Boosting CAR T Cell Therapy for Solid Tumors
Boosting CAR T Cell Therapy for Solid Tumors
The Scientist Creative Services Team in Collaboration with IsoPlexis | Apr 5, 2021
Katie McKenna will discuss how oncolytic viral therapy enhances CAR-T cell killing of cancer cells.
Cancer Vaccines: Raising a T Cell Army
Cancer Vaccines: Raising a T Cell Army
The Scientist Creative Services Team | Apr 1, 2021
Vaccines against various forms of cancer prime the immune system to attack.
Surveillance Gaps: How Cancer Arises
Surveillance Gaps: How Cancer Arises
The Scientist Creative Services Team | Mar 15, 2021
Surveillance Gaps: How Cancer Arises
Bispecific Antibodies Treat Cancer in Mouse Models
Bispecific Antibodies Treat Cancer in Mouse Models
Abby Olena | Mar 5, 2021
A trio of papers shows that specialized antibodies can direct T cells to destroy cells that display portions of mutant cancer-related proteins, as well as T cells that have become cancerous themselves.
Fecal Transplant Could Boost Immunotherapy to Treat Melanoma
Fecal Transplant Could Boost Immunotherapy to Treat Melanoma
Shawna Williams | Feb 12, 2021
The results from two Phase 1 trials bolster the case that the gut microbiome plays a role in response to the drugs.
The Scientist Speaks Podcast - Episode 10
The Scientist Speaks Podcast - Episode 10
The Scientist Creative Services Team | Oct 28, 2020
Cancer Immunotherapy: CRISPR Reveals Targets In Vivo
Longitudinal Immune Profiling Reveals Key Immune Signatures Associated with COVID-19
Longitudinal Immune Profiling Reveals Key Immune Signatures Associated with COVID-19
The Scientist Creative Services Team | Sep 14, 2020
Madhvi Menon will discuss immune profiling of COVID-19 patients and Jyoti Phatak-Sheldon will highlight the use of RNAscope in situ hybridization in SARS-CoV-2 research.
Infographic: How Immunotherapy Could Boost Stem-Like T Cells
Infographic: How Immunotherapy Could Boost Stem-Like T Cells
Daniel E. Speiser and Werner Held | Jul 13, 2020
Cancer therapies could potentially be more effective if their development took into account the cells that give rise to tumor-fighting cells.
Contributors
Contributors
The Scientist Staff | Jul 13, 2020
Meet some of the people featured in the July/August 2020 issue of The Scientist.
Harnessing Stem Cell–Like T Cells to Better Fight Cancer
Harnessing Stem Cell–Like T Cells to Better Fight Cancer
Daniel E. Speiser and Werner Held | Jul 13, 2020
Better understanding the CD8+ T cells already present in tumors could be key to making immunotherapies work for more patients.
Natural Killer Cell Therapies Catch Up to CAR T
Natural Killer Cell Therapies Catch Up to CAR T
Bianca Nogrady | Apr 1, 2020
There’s a new cell-based cancer immunotherapy on the block.
Flu Shot Ignites Immune Attack Against Cancer in Mice
Flu Shot Ignites Immune Attack Against Cancer in Mice
Ashley Yeager | Apr 1, 2020
Injecting the seasonal flu vaccine directly into clumps of malignant cells recruits immune cells to confront the cancer.
CAR T Cell Adds Scorpion Venom to Tackle Tumor Heterogeneity
CAR T Cell Adds Scorpion Venom to Tackle Tumor Heterogeneity
Amy Schleunes | Mar 24, 2020
A newly engineered CAR T cell that incorporates a peptide isolated from the venom of the deathstalker scorpion has broad brain tumor–binding capabilities that will be investigated in an upcoming clinical trial.
Novel DNA-Sensing Pathway Found in Human Cells, Absent in Mice
Novel DNA-Sensing Pathway Found in Human Cells, Absent in Mice
Catherine Offord | Jan 24, 2020
This previously unknown mechanism for spotting foreign genetic material in the cytoplasm launches antiviral defenses even when the well-known immune mediator STING is absent.